T1	Participants 58 124	patients with type 2 diabetes mellitus and coronary artery disease
T2	Participants 334 385	patients receiving dual antiplatelet therapy (DAPT)
T3	Participants 1380 1428	total of 40 patients were available for analysis
T4	Participants 898 998	Patients were randomly assigned to either pentoxifylline 400 mg or placebo 3 times daily for 14 days
